AbsTrACT
Objectives patients with difficult-to-treat rheumatoid arthritis (rA) remain symptomatic despite treatment according to current european League Against rheumatism (eULAr) management recommendations. these focus on early phases of the disease and pharmacological management. We aimed to identify characteristics of difficult-to-treat rA and issues to be addressed in its workup and management that are not covered by current management recommendations. Methods An international survey was conducted among rheumatologists with multiple-choice questions on disease characteristics of difficult-to-treat rA. Using open questions, additional items to be addressed and items missing in current management recommendations were identified. results 410 respondents completed the survey: 50% selected disease activity score assessing 28 joints >3.2 or presence of signs suggestive of active disease as characteristics of difficult-to-treat rA; 42% selected fatigue; 48% selected failure to ≥2 conventional synthetic disease-modifying antirheumatic drugs (DMArDs) AnD ≥2 biological/targeted synthetic DMArDs; 89% selected inability to taper glucocorticoids below 5 mg or 10 mg prednisone equivalent daily. interfering comorbidities, extra-articular manifestations and polypharmacy were identified as important issues missing in current management recommendations. Conclusions there is wide variation in concepts of difficult-to-treat rA. several important issues regarding these patients are not addressed by current eULAr recommendations.
InTrOduCTIOn
The European League Against Rheumatism (EULAR) recommendations and the American College of Rheumatology guidelines on management of rheumatoid arthritis (RA) focus on early phases of the disease and on pharmacological management. 1 2 These recommendations suggest intensifying the disease-modifying antirheumatic drug (DMARD) strategy, if improvement or the treatment target is not achieved within 3 or 6 months, respectively. Nevertheless, a significant proportion of patients remains symptomatic after several cycles of treatment, which makes them difficult to treat; this is a significant clinical problem in daily practice. 3 A wide array of potential factors contributes to difficult-to-treat RA, such as DMARD resistance or intolerance, adverse reactions, treatment non-adherence and limited drug options due to comorbidities. Importantly, patients with RA may also remain symptomatic due to non-inflammatory factors, such as secondary osteoarthritis, pain syndromes, social and occupational decline and coping difficulties. All these may (in different combinations) play a role in individual patients and require specific management approaches, which should be addressed in management recommendations.
Currently, different concepts exist on difficultto-treat RA, such as refractory, multidrug resistant or persistent RA, or concepts based on number of failed DMARDs and failed treatment goals. [4] [5] [6] [7] Depending on the criteria used, the estimated prevalence of difficult-to-treat RA ranges from 5% to 20%. 6 We aimed to identify characteristics of the concept of difficult-to-treat RA and to explore issues to be addressed in its workup and management that are not covered by current EULAR management recommendations.
MeTHOds

Online survey among rheumatologists
An online survey (online supplementary file 1, set up by DvdH, GN, JWGJ, JMvL, MJHdH and PMJW) was conducted among rheumatologists (including rheumatologists-in-training). The survey was distributed by email in the network of the authors and by Emerging EULAR Network (EMEUNET) and it was asked to additionally forward it to other rheumatologists. The survey consisted of two questions regarding the background of the respondents (Where do you work? How many RA patients do you treat?).
Four multiple-choice questions addressed the perceived necessity of incorporating the following items, and their cut-offs, into the concept of difficult-to-treat RA: disease activity level; presence of fatigue; number of DMARDs that failed; and inability to taper glucocorticoid (GC) treatment. Only one response option could be selected at Clinical and epidemiological research each multiple-choice item, which were selected as -according to expert opinion -being among the most frequent and relevant characteristics in clinical practice. Fatigue was selected as one of the most relevant patient reported outcomes in RA. 8 Three open questions were: 'Please define any additional characteristics and suggested criteria for difficult-to-treat RA'; 'Please mention additional clinical issues or comorbidities to be addressed in the workup and management of these patients'; and 'Please mention any clinically relevant situations which are not covered by the current RA EULAR recommendations'.
Qualification and quantification of the responses to the open questions
NMTR and MJHdH independently classified the responses to the open questions into categories (online supplementary file 1). This enabled summarising and quantifying. Categories were defined based on the responses that were given to the open questions. One response could fit multiple categories. 'Other' was used to classify characteristics that did not fit into one of the categories. Discrepancies in classification between NMTR and MJHdH were resolved by consensus.
statistical analyses
All responses were evaluated using descriptive statistics, performed using IBM SPSS Statistics V.21 software.
resulTs respondents
Four hundred and ten respondents from 33 countries completed the survey between July 2017 and March 2018. Of the 385 respondents who filled out the name of their country, 96% was European (figure 1). Twenty-five per cent of the respondents (n=7 missing) treated <100 unique patients with RA, 42% 100-300 patients and 32% >300 patients.
selected difficult-to-treat rA disease characteristics
Fifty per cent of respondents selected 'disease activity score assessing 28 joints using erythrocyte sedimentation rate (DAS28-ESR) >3.2 OR presence of signs suggestive of active inflammatory disease activity with a DAS28-ESR ≤3.2' as characteristics ( figure 2A ). Forty-two per cent included fatigue (figure 2B). Forty-eight per cent selected '≥2 conventional synthetic (cs) DMARDs AND ≥2 biological (b) DMARDs or targeted synthetic (ts) DMARDs with different modes of action' for how many insufficiently effective antirheumatic drugs should at least have been applied (figure 2C). Eighty-nine per cent selected inability to taper GCs <5 mg (43%) or 10 mg (46%) prednisone or equivalent daily for more than 1 year, irrespective of DMARD treatment (figure 2D), as difficult-to-treat RA characteristic.
Additional difficult-to-treat rA characteristics
Two hundred and forty-three additional characteristics of difficult-to-treat RA were given by 169 respondents (figure 2E), most frequently categorised into 'interfering comorbidities' and 'extra-articular manifestations'. Examples are cardiovascular risk, malignancies, interstitial lung disease and vasculitis. A diversity of 'other' responses was given, for example, inflammation on MRI, morning stiffness and patient dissatisfaction.
Interfering clinical issues and items missing in current eulAr recommendations important to manage difficult-to-treat rA
For interfering issues to be addressed in the workup and management of difficult-to-treat RA, 396 suggestions were given by 170 respondents (figure 3A), most frequently cardiovascular disease and extra-articular manifestations. Other interfering clinical issues were drug intolerance, smoking and chronic liver disease.
For issues not covered by the current EULAR recommendations, 64 were mentioned by 54 respondents (figure 3B). These were most frequently classified as interfering comorbidities and extra-articular manifestations. Also issues regarding pharmacological management (eg, tapering regimen, adverse events and polypharmacy), pain syndromes and pregnancy and lactation were mentioned. Other items were ongoing joint destruction, coping problems and persistent single joint involvement.
dIsCussIOn
Our results show a wide variety in concepts of difficult-to-treat RA; active disease, failure to DMARD treatment and inability to taper GCs are considered main characteristics. Additional difficult-to-treat RA characteristics were mostly related to extra-articular manifestations and interfering comorbidities that may hamper assessment of disease activity or limit treatment possibilities. As items missing in current RA EULAR management Figure 2 Difficult-to-treat RA characteristics. b/tsDMARDs, biological/targeted synthetic disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic DMARDs; DAS28-ESR, disease activity score assessing 28 joints using erythrocyte sedimentation rate; RA, rheumatoid arthritis; US, ultrasonography. * with different modes of action; ° or equivalent daily for more than 1 year, irrespective of DMARD treatment.
recommendations, interfering comorbidities (especially cardiovascular disease, infection and malignancy), extra-articular manifestations, pharmacological management (eg, tapering strategies, adverse events and polypharmacy) and pain syndromes were mentioned most frequently.
Of the factors mentioned as contributing to difficult-to-treat RA in this survey, for example treatment non-adherence, adverse events and coping strategies, exact prevalences are unknown. These should be determined in future research for an indication of their need to be included in management recommendations.
Our results mainly reflect how difficult-to-treat RA is experienced in European countries. Additional contributing factors to difficult-to-treat RA in countries outside Europe might be limited access to diagnostic tests, to rheumatologists and to DMARDs. These should be addressed in management recommendations as well.
Our study has limitations. The survey was distributed via email, and it was asked to forward it to other rheumatologists to increase the number of respondents. As a drawback, the total number of rheumatologists who received it is unknown.
The four multiple-choice questions had prespecified response options, limiting input to these questions but enabling the responses to be easily summarised and quantified. The open questions required a classification system for the responses; some responses were classified into two categories, and there was a number of responses that was classified as 'other'. Additionally, the prespecified multiple-choice questions may have biased the results of the open questions. However, by these open questions, we received a large inventory of issues that may need to be addressed in clinical practice.
The strengths of this study are the large number of respondents and of European countries represented by the respondents; the Clinical and epidemiological research Recently, a EULAR Task Force has been initiated on the development of recommendations for the comprehensive management of difficult-to-treat RA. The results of this survey will fuel discussions on items to include in the management recommendations of difficult-to-treat RA.
In conclusion, the results of this survey underscore the difficulty in establishing an unambiguous concept of difficult-to-treat RA, which is seen as a heterogeneous condition not fully covered by current EULAR recommendations. The recently established EULAR Task Force will explore the management of difficult-totreat RA further.
